Laser Photobiomodulation to Prevent Oral Mucositis and Functional Impairment in Adults With Hematologic Cancer Undergoing Stem Cell Transplantation

What this Trial Is About

Researchers are evaluating the use of laser photobiomodulation to prevent oral mucositis and functional impairments in adults with hematologic cancer undergoing hematopoietic stem cell transplantation (HSCT). The study aims to compare the effectiveness and patient acceptability of photobiomodulation in the oral cavity against standard care. This randomized controlled trial includes adults aged 18 to 65 years with hematological neoplasms who require HSCT. Participants will be randomly assigned to receive either photobiomodulation plus usual care or usual care alone. Photobiomodulation involves daily sessions using a diode laser device with specific parameters, applied to multiple points inside the mouth from the first day of conditioning until three days after transplant. Usual care includes education, cryotherapy, and mouth hygiene. The intervention group receives laser treatment sessions lasting about 5 to 10 minutes each. During the study, researchers will monitor oral mucositis daily up to 20 days after transplant or until hospital discharge. They will also assess pain levels, handgrip strength, exercise tolerance, physical fitness, quality of life, nutritional status, and other health measures through the hospital stay, averaging about one month. Patient adherence and acceptability of the laser treatment will be recorded. Evaluations occur at admission before conditioning and at discharge to understand the laser's impact and patient experience.

Photobiomodulation for Oral Mucositis and Functional Impairments During Hematopoietic Stem Cell Transplantation